51.30 -0.31 (-0.61%)
After hours: 4:11PM EDT
|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's Range||50.52 - 51.75|
|52 Week Range||32.53 - 59.59|
|Beta (3Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.64|
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will webcast a live presentation from its Pulmonary Arterial Hypertension (PAH) Research and Development Deep Dive event on Friday, November 16, 2018. The meeting will feature presentations from leading PAH clinicians and researchers along with Acceleron senior management, who will discuss the current PAH treatment landscape and the importance of BMP signaling—a molecular pathway fundamental to all forms of the disease. The Company will highlight its latest preclinical research on sotatercept, its lead product candidate in PAH, which will have been presented at the American Heart Association Scientific Sessions on November 10-12, 2018.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver poster presentations on ACE-083 from Part 1 of each its ongoing Phase 2 trials in patients with facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease (CMT) at the 23rd International Annual Congress of the World Muscle Society to be held in Mendoza, Argentina, October 2-6, 2018.
NEW YORK, NY / ACCESSWIRE / September 20, 2018 / Wall Street posted mixed results on Wednesday as tech shares weakened and trade tensions continued to rise. The Dow Jones Industrial Average gained 0.61 ...
Acceleron Pharma Inc (NASDAQ: XLRN ) has a rich pipeline that positions the stock for additional upside, according to Piper Jaffray. The Analyst Analyst Danielle Brill upgraded Acceleron from Neutral to ...
Biotech giant Celgene could go private at 120 per share, an analyst suggested Wednesday after similarly sized electric-car maker Tesla confirmed it's discussing the possibility.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...
Acceleron (XLRN) delivered earnings and revenue surprises of 1.56% and 7.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 63 cents. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Acceleron Pharma (NASDAQ: XLRN ) releases its next round of earnings Thursday. Here's Benzinga's essential guide to Acceleron Pharma's Q2 earnings report. Earnings and Revenue Based on management's projections, ...
Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.m. EDT to discuss its second quarter 2018 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
On July 9, Celgene (CELG) and Acceleron Pharma announced their results from the Phase 3 BELIEVE trial. Celgene and Acceleron conducted the Phase 3 BELIEVE trial to evaluate the safety and efficacy of luspatercept and the best supportive care compared to a placebo and the best supportive care for the treatment of adult individuals with transfusion-dependent beta thalassemia.
On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: Brookdale Senior Living Inc. (NYSE: BKD), Envision Healthcare Corp. (NYSE: EVHC), Genesis Healthcare Inc. (NYSE: GEN), and Acceleron Pharma Inc. (NASDAQ: XLRN).
Acceleron Pharma Inc (NASDAQ: XLRN) shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes. The rally sent Morgan Stanley analyst Matthew Harrison to the sidelines. Acceleron's luspatercept data is strong, positioning the company for a filing in the first half of 2019, but there is possibility of limited near-term upside, Harrison said in a Friday morning note.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Company’s locally acting “Myostatin+” muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD). “We are pleased to receive orphan drug designation for ACE-083, which has shown the potential to address an area of high unmet medical need,” said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron.
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...